Tajikistan Emergency COVID-19 Project (P173765)

EUROPE AND CENTRAL ASIA | Tajikistan | Health, Nutrition & Population Global Practice | IBRD/IDA | Investment Project Financing | FY 2020 | Seg No: 6 | ARCHIVED on 29-Jun-2023 | ISR57036 |

Implementing Agencies: Ministry of Health and Social Protection, Republic of Tajikistan, State Agency for Social Protection

Key Dates

Key Project Dates

Bank Approval Date: 02-Apr-2020 Effectiveness Date: 24-Apr-2020

Planned Mid Term Review Date: 28-Jan-2022 Actual Mid-Term Review Date: 03-May-2022

Original Closing Date: 01-Dec-2021 Revised Closing Date: 30-Nov-2023

Project Development Objectives

Project Development Objective (from Project Appraisal Document)

Project Development Objective (PDO) is to prepare and respond to the COVID-19 pandemic in the Republic of Tajikistan.

Has the Project Development Objective been changed since Board Approval of the Project Objective?

Yes

Public Disclosure Authorized

Board Approved Revised Project Development Objective (If project is formally restructured)

Project Development Objective (PDO) is to prevent, prepare and respond to the COVID-19 pandemic in the Republic of Tajikistan.

Components

Name

Component 1. Strengthening Intensive Care Capacity and COVID-19 Prevention:(Cost \$42.96 M)

Component 2. Multi-sectoral response planning and community preparedness: (Cost \$1.44 M)

Component 3. Temporary social assistance for vulnerable households: (Cost \$11.32 M)

Component 4. Project Implementation and Monitoring:(Cost \$1.80 M)

Overall Ratings

Name	Previous Rating	Current Rating
Progress towards achievement of PDO	□Satisfactory	□Satisfactory
Overall Implementation Progress (IP)	□Satisfactory	□Satisfactory
Overall Risk Rating	Substantial	Substantial

Implementation Status and Key Decisions

Since the last progress assessment in December 2022, good progress towards achieving the Project objectives has been made. The COVID-19 vaccines procured by the Project have been fully utilized and contributed to the achievement of the national COVID-19 vaccination program targets. The rollout of the electronic COVID-19 vaccination system has continued, with nearly 3,000,000 vaccination records entered. The data entered allow for disaggregating the number of persons vaccinated by age and gender. The Project's four key performance indicators have reached or exceeded their end targets: 1) Intensive care units if 10 hospitals have been fully equipped increasing the overall intensive care capacity in the country by 100 beds (actual: 100, planned: 100); 2) Number of vulnerable households who received targeted cash assistance financed by the

6/29/2023 Page 1 of 9 Project (actual: 233,982 as compared to planned 100,000); 3) Number of oxygen stations procured by the Project (actual: 15, planned: 15); 4) Percentage of population vaccinated, which is included in the priority population targets defined in national plan (actual: 57, as compared to the planned 28).

MPA Program Development Objective

The Program Development Objective is to prevent, detect and respond to the threat posed by COVID-19 and strengthen national systems for public health preparedness

Multiphase Programmatic Approach (MPA) Status

Sustained efforts continue to be made to advance the implementation of the 87 MPA operations. As of June 15, 2023, 88 MPA-projects have been approved with a total commitment of US\$4.3 billion. One operation (Guatemala) was cancelled in mid-September 2021, at the request of the Government. **Total disbursements as of June 15, 2023, amount to US\$3.89 billion or 91% of overall commitments.** This amount does not include disbursements under MPA-V operations which are reported together with AF-V operations. A large refund from the UN to the project account of the Myanmar operation was processed in late March due to the inability to implement the project. This transaction affected total disbursements. Also, (i) Loans and Credits denominated in SDRs and Euros are being affected because of fluctuations between the SDRs and Euros against the US dollar, and (ii) at this late stage of project implementation, several operations are processing refunds to the special/project accounts, which have an impact on total disbursements. Thirteen operations closed by the end of CY22. Thirty five operations have closing dates by the end of CY23. However, there are several projects that are/will be processing extensions so this number is likely to change.

As with the Mid Term Review issued on March 25, 2023, no individual COVID-19 MPA operation will have to complete an ICR. Instead, one ICR will be prepared for the entire COVID-19 MPA Program after the closing date of the Program -- December 31, 2025. This Global ICR will be based on final ISRs packages prepared by country operations' teams. A template for the final ISR was issued by OPCS on March 25, 2022. Several operations have/are preparing final ISR packages. The overall conclusion of the MTR was that the COVID-19 MPA Program embodied a rapid, innovative approach to new lending for human health response. The MTR concluded that the COVID-19 MPA has been successful, notwithstanding considerable uncertainty and multiple constraints in the early stages of the pandemic. The Bank's emergency response was remarkably swift in the most vulnerable countries facing human capital losses and development setbacks. Further, the MTR concluded that notwithstanding the challenges, the MPA is on track to achieve its PrDO, "prevent, detect and respond to the threat posed by COVID-19 and strengthen national systems for public health preparedness."

Seventy one (71) country projects or 83 percent of projects approved have reached 70-100+ percent disbursement (reasons for >100% disbursements relate to fluctuations between the Euro and the SDR against the US\$). Out of the 71 operations, 59 operations or 83% have disbursed 90+% of commitments. Out of the 71 operations, 38 operations are fully disbursed and sixteen (16) operations have disbursed 95-99% of commitments. As reported in mid-April, there are six operations with disbursements of 50 percent or less. Out of these six operations, one has not disbursed (AFW), and one operation has disbursed 30 percent (AFW). The projects are benefitting around 3.7 billion people or 50% of the global population. When countries with AF-V operations are counted, the projects are benefitting 4.1 billion of 51 percent of the global population. This is because some countries that do not have a parent project have AF-V operations. Eighty-six (86) or 99% of projects approved are disbursing. ECA has the highest percentage of disbursements at 99%, followed by MNA with 96%, SAR with 94%, LAC with 92%, EAP with 85%, AFE and AFW with 78%. Disbursements for EAP operations are being affected by relatively low disbursements in Fiji, Kiribati, Samoa, and Solomon Islands. AFE lower disbursements compared to other regions are a result of low disbursements under two operations. In the case of AFW low overall disbursements are a result of no disbursements under one operation and only 30 percent under another. Retroactive Financing (RF)

6/29/2023 Page 2 of 9

continues to represent 20 percent of commitments. SAR has the highest percentage of RF at 37 percent, followed by ECA at 18 percent. IDA continues to represent 39 percent and IBRD 41 percent of disbursements.

Streamlined procedures, delegated approvals, coupled with flexible project design and intensified efforts across the Bank have contributed to the progress. Implementation is being guided by Bank teams working in parallel with other health related projects, including Additional Financing operations supporting vaccine procurement and deployment efforts.

The Additional Financing (MPA AF-V) to the COVID-19 Strategic Preparedness and Response Program utilizing the Multiphase Programmatic Approach (COVID-19 MPA) was approved by the Board on October 13, 2020. The AF-V was approved with an envelope of US\$12 billion (\$6 billion from IDA and \$6 billion from IBRD) in financing. The AF-V is expected to enable vaccination for up to 750 million people, with potential surge capacity for an additional 250 million people in the poorest countries while scaling support to strengthen immunization delivery, with design flexibility at the country level.

No additional AF-V operation has been approved since late October 2022. As of June 15, 2023, the Bank has approved 113 operations to support vaccine procurement and rollout in 78 countries. A new operation is being processed in Senegal. One hundred and sixteen (116) operations had been approved amounting to \$10 billion, but: (i) the Costa Rica operation (\$120 million), (ii) the Peru operation (\$500 million), and the (iii) Gabon (\$12 million) were cancelled at the request of the governments. Also, the Afghanistan operation commitment of \$113 million was reduced to \$60 million. Total commitment for the 113 operations is \$9.19 billion. The 113 operations approved, include 6 operations that involved restructuring of parent projects (Bhutan, Cameroon, North Macedonia, Philippines, and Pakistan) and in the case of Lebanon, restructuring of the Health Resilience Project. Of the 113 approved operations: (i) 63 are in Africa – 29 in AFE and 34 in AFW; (ii) 10 in East Asia and the Pacific; (iii) 11 in Europe and Central Asia; (iv) 11 in Latin America and the Caribbean; (v) 9 in Middle East and North Africa; and (vi) 9 in South Asia. Thirty-two operations are being implemented in Fragile and Conflict-affected situations. IDA continues to represent 43 percent and IBRD 57 percent of disbursements. Total disbursements under these projects as of June 15, 2023, amount to US\$5.84 billion or 64 percent of overall commitments. Disbursements under MPA-V operations are included in this total while disbursements under the six restructured projects are counted under parent projects. With less than planned demand for IDA/IBRD funds for vaccine procurement because, inter alia, over supply of vaccines from donations from various sources, several projects are being and more will need to be restructured to reallocate funds allocated for procurement of COVID-19 vaccines and deployment. A Guidance Note has been prepared by HNP together with OPCS and other departments to seek approval by management for utilization of undisbursed funds. The Note will provide guidance to teams regarding the utilization of committed but unused funds under AF-V operations for the procurement of commodities, including routine vaccines.

Thirty-six (36) AF-V/MPA-V operations or 32% of operations approved have disbursed over 70% of their commitments. Out of the 36, twelve operations or 33% have disbursed 90+. Out of the 12, three operations are fully disbursed (Argentina, Sri Lanka AF-V 1, and Ukraine AF-V 3). Five operations have disbursed 98-99% of commitments (Ecuador AF-V 1, Indonesia, Iraq, Sierra Leone AF-V 1, and Yemen). Seven operations have disbursed 95-99%. Ninety-one (91) operations or 81 percent of total operations approved are disbursing. ECA has the highest percentage of disbursements at 85%, followed by SAR at 77%, EAP at 72%, LAC at 69%, MNA at 65%, AFE at 52% and AFW at 48%.

Retroactive Financing (RF) represents 37 percent of overall commitments. High levels of RF have been authorized under different operations - Ukraine (100%), Panama and Turkey (90%), Argentina and Guyana (80%), and Belize, and Sri Lanka (70%). One hundred and thirteen (113) loan/financing agreements or 100 percent of projects approved have been signed. One hundred and twelve (112) loan/financing agreements or 99 percent of projects approved have become effective. As with the COVID-19 MPA operations, streamlined procedures, delegated approval, wide use of Bank Facilitated Procurement, coupled with flexible project design, and intensified efforts across the Bank have contributed to the rapid design, processing, and implementation of the AF-V operations.

6/29/2023 Page 3 of 9

Risks

Systematic Operations Risk-rating Tool

Risk Category	Rating at Approval	Previous Rating	Current Rating
Political and Governance	Substantial	Substantial	Substantial
Macroeconomic	□High	Substantial	Moderate
Sector Strategies and Policies	Substantial	□Moderate	Moderate
Technical Design of Project or Program	□Moderate	□Moderate	Moderate
Institutional Capacity for Implementation and Sustainability	□Moderate	□Moderate	□Moderate
Fiduciary	Substantial	□Moderate	Substantial
Environment and Social	Substantial	Substantial	Substantial
Stakeholders	□Moderate	□Moderate	Moderate
Other		Substantial	Substantial
Overall	Substantial	Substantial	Substantial

Results

PDO Indicators by Objectives / Outcomes

To prevent, prepare and respond to the COVID-19 pandemic in the Republic of Tajikistan.

► Number of beds in fu	lly equipped and functional inter	nsive case units (ICUs) financed	d by the project (Number, C	Custom)
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	100.00	100.00	100.00
Date	01-Apr-2020	11-Oct-2022	19-Jun-2023	30-Nov-2023
Comments:	Target has been ach	nieved.		
➤ Number of oxygen st	ations procured by the Project (I	Number, Custom)		
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	15.00	15.00	15.00
Date	14-Jan-2021	11-Oct-2022	19-Jun-2023	30-Nov-2023
Comments:	Target has been ach	nieved.		

6/29/2023 Page 4 of 9

► Percentage of population vaccinated,	which is included in the priority population	targets defined in national plan	[disaggregated by gender].
(Percentage, Custom)			

	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	55.30	57.00	28.00
Date	14-Jan-2021	11-Oct-2022	19-Jun-2023	30-Nov-2023
Comments:	Target, which captu	res the national vaccination co	verage, has been exceeded	l.

To prevent, prepare and respond to the COVID-19 pandemic in the Republic of Tajikistan.

▶ Number of vulnerable households who received targeted cash assistance financed by the project (Number, Custom)

	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	219,480.00	233,982.00	100,000.00
Date	01-Apr-2020	11-Oct-2022	19-Jun-2023	30-Nov-2023
Comments:		ive number of vulnerable hou e Project, has been exceeded		e targeted cash

Intermediate Results Indicators by Components

Strengthening intensive care capacity and COVID-19 prevention.

► Number of PPE units procured by the project. (Number, Custom)

	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	448,320.00	637,000.00	500,000.00
Date	01-Apr-2020	11-Oct-2022	19-Jun-2023	30-Nov-2023
Comments:	Target has been excee	eded		

▶ Number of ventilators procured by the project. (Number, Custom)

	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	68.00	68.00	68.00
Date	01-Apr-2020	11-Oct-2022	19-Jun-2023	30-Nov-2023
Comments:	Target has been achieved	I		

► Number of COVID -19 test kits procured by the project. (Number, Custom)

6/29/2023 Page 5 of 9

			A -t (Ot)	Fra d Tanasah
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	150,000.00	500,000.00	400,000.00
Date	01-Apr-2020	11-Oct-2022	19-Jun-2023	30-Nov-2023
Comments:	Target has been ex	ceeded		
► Number of MMR vac	cine doses procured by the Proj	ect (Number, Custom)		
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	514,000.00	3,092,000.00	4,000,000.00
Date	14-Jan-2021	11-Oct-2022	19-Jun-2023	30-Nov-2023
Comments:	Indicator on track to	be achieved		
► Health information sy	ystem collecting sex and age dis			
			Actual (Current)	End Target
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	Baseline No	Yes	Yes	Yes
Value	No 17-Dec-2021	Yes 11-Oct-2022		
	No	Yes 11-Oct-2022	Yes	Yes
Date Comments:	No 17-Dec-2021	Yes 11-Oct-2022 ceeded	Yes 19-Jun-2023	Yes 30-Nov-2023
Date Comments: ►Number of COVID-19	No 17-Dec-2021 Target has been exc	Yes 11-Oct-2022 ceeded	Yes 19-Jun-2023	Yes 30-Nov-2023
Date Comments: ►Number of COVID-19	No 17-Dec-2021 Target has been executed free of charget free	Yes 11-Oct-2022 ceeded rge by the laboratories receiving	Yes 19-Jun-2023 G COVID-19 tests procured	Yes 30-Nov-2023 by the project (Number,
Date Comments: ► Number of COVID-19 Custom)	No 17-Dec-2021 Target has been executed free of charges administered free of charges as a second s	Yes 11-Oct-2022 ceeded rge by the laboratories receiving Actual (Previous)	Yes 19-Jun-2023 G COVID-19 tests procured Actual (Current)	Yes 30-Nov-2023 by the project (Number, End Target
Date Comments: Number of COVID-19 Custom) Value	No 17-Dec-2021 Target has been exectly as a second of the second of th	Yes 11-Oct-2022 ceeded rge by the laboratories receiving Actual (Previous) 0.00	Yes 19-Jun-2023 G COVID-19 tests procured Actual (Current) 0.00 11-Oct-2022	Yes 30-Nov-2023 by the project (Number, End Target 400,000.00
Date Comments: Number of COVID-19 Custom) Value Date Comments:	No 17-Dec-2021 Target has been exectly as a second of the second of th	Yes 11-Oct-2022 ceeded rge by the laboratories receiving Actual (Previous) 0.00 11-Oct-2022 eved. Data from the laboratories	Yes 19-Jun-2023 g COVID-19 tests procured Actual (Current) 0.00 11-Oct-2022 s is pending.	Yes 30-Nov-2023 by the project (Number, End Target 400,000.00 30-Nov-2023
Date Comments: Number of COVID-19 Custom) Value Date Comments:	No 17-Dec-2021 Target has been except the second of the	Yes 11-Oct-2022 ceeded rge by the laboratories receiving Actual (Previous) 0.00 11-Oct-2022 eved. Data from the laboratories	Yes 19-Jun-2023 g COVID-19 tests procured Actual (Current) 0.00 11-Oct-2022 s is pending.	Yes 30-Nov-2023 by the project (Number, End Target 400,000.00 30-Nov-2023
Date Comments: Number of COVID-19 Custom) Value Date Comments:	No 17-Dec-2021 Target has been except the second of the	Yes 11-Oct-2022 ceeded rge by the laboratories receiving Actual (Previous) 0.00 11-Oct-2022 eved. Data from the laboratories alled at rayonal, oblast, and cer	Yes 19-Jun-2023 G COVID-19 tests procured Actual (Current) 0.00 11-Oct-2022 is is pending.	Yes 30-Nov-2023 by the project (Number, End Target 400,000.00 30-Nov-2023
Date Comments: Number of COVID-19 Custom) Value Date Comments: Number of medical was a second content of medical was a s	No 17-Dec-2021 Target has been except the second of the	Yes 11-Oct-2022 ceeded rge by the laboratories receiving Actual (Previous) 0.00 11-Oct-2022 eved. Data from the laboratories alled at rayonal, oblast, and cer Actual (Previous)	Yes 19-Jun-2023 G COVID-19 tests procured Actual (Current) 0.00 11-Oct-2022 s is pending. Actual (Number, Custom Actual (Current)	Yes 30-Nov-2023 by the project (Number, End Target 400,000.00 30-Nov-2023

Multi-sectoral response planning and community preparedness.

6/29/2023 Page 6 of 9

► Number of communi	ty volunteers trained by the proje	ect (Number, Custom)			
	Baseline	Actual (Previous)	Actual (Current)	End Target	
Value	0.00	1,000.00	1,000.00	500.00	
Date	01-Apr-2020	11-Oct-2022	19-Jun-2023	30-Nov-2023	
	Target has been exc	Target has been exceeded			
Comments:					
► Number of journalists	s trained by the Project who repo back (Number, Custom)		upported their ability to sha	re official information and	
► Number of journalists	s trained by the Project who repo		upported their ability to sha Actual (Current)	re official information and End Target	
► Number of journalists	s trained by the Project who repo back (Number, Custom)	ort that the training effectively s	,		
►Number of journalists report beneficiary feedt	s trained by the Project who repo back (Number, Custom) Baseline	ort that the training effectively so	Actual (Current)	End Target	

Project Implementation and Monitoring

▶ Percentage of grievances addressed within the time specified in the project implementation manual (Percentage, Custom)

	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	100.00	100.00	80.00
Date	01-Apr-2020	11-Oct-2022	11-Oct-2022	30-Nov-2023
Comments:	Target has been exceede	ed		

► Semi-annual project monitoring reports include a section with feedback from civil society and reporting on actions taken that is publicly disclosed (Yes/No, Custom)

	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	No	Yes	Yes	Yes
Date	14-Jan-2021	11-Oct-2022	19-Jun-2023	30-Nov-2023
Comments:	Target has been achieved	l.		

Temporary social support for vulnerable households

▶ Beneficiaries of social safety net programs (Number, Corporate)

	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	219,480.00	233,982.00	100,000.00

6/29/2023 Page 7 of 9

te	01-Apr-2020	11-Oct-2022	19-Jun-2023	30-Nov-2023				
mments:	Target has been ex	Target has been exceeded						
□Beneficiaries of Safety Nets programs - Unconditional cash transfers (number) (Number, Corporate Breakdown)								
	Baseline	Actual (Previous)	Actual (Current)	End Target				
alue	0.00	219,480.00	233,982.00	100,000.00				
ate	01-Apr-2020	11-May-2022	19-Jun-2023	30-Nov-2023				
	<u> </u>	,						
	<u> </u>	11-May-2022 It targeted cash assistance finar						
	<u> </u>	,						
	ded households who received	I targeted cash assistance finar	nced by the Project (Numbe	r, Custom)				
Number of female-head	ded households who received Baseline	d targeted cash assistance finar Actual (Previous)	nced by the Project (Numbe Actual (Current)	r, Custom) End Target				

Performance-Based Conditions

Data on Financial Performance

Disbursements (by loan)


Project	Loan/Credit/TF	Status	Currency	Original	Revised	Cancelled	Disbursed	Undisbursed	% Disbursed
P173765	IDA-D6040	Effective	USD	11.30	11.30	0.00	11.59	0.00	100%
P173765	IDA-D7760	Effective	USD	8.63	8.63	0.00	7.87	0.55	93%
P173765	IDA-D7770	Effective	USD	12.57	12.57	0.00	12.36	0.00	100%
P173765	IDA-D9620	Effective	USD	25.00	25.00	0.00	10.63	13.45	44%

Key Dates (by Ioan)

Project	Loan/Credit/TF	Status	Approval Date	Signing Date	Effectiveness Date	Orig. Closing Date	Rev. Closing Date
P173765	IDA-D6040	Effective	02-Apr-2020	03-Apr-2020	24-Apr-2020	01-Dec-2021	31-Jul-2023
P173765	IDA-D7760	Effective	11-Feb-2021	21-May-2021	30-Jun-2021	31-Jul-2022	30-Nov-2023
P173765	IDA-D7770	Effective	11-Feb-2021	21-May-2021	30-Jun-2021	31-Jul-2022	31-Jul-2023
P173765	IDA-D9620	Effective	21-Dec-2021	14-Mar-2022	11-Jul-2022	31-Jul-2023	30-Nov-2023

6/29/2023 Page 8 of 9

Cumulative Disbursements



Restructuring History

Level 2 Approved on 04-Aug-2021 ,Level 2 Approved on 25-Nov-2021 ,Level 2 Approved on 03-Mar-2023

Related Project(s)

P175168-Additional Financing for the Tajikistan Emergency COVID-19 Project ,P176216-Additional Financing for the Tajikistan Emergency COVID-19 Project ,P177780-Additional Financing and Restructuring of the Tajikistan COVID-19 Project

6/29/2023 Page 9 of 9